Latest Options Exercise News

Emmerson Resources is set to be acquired by Pan African Resources for approximately A$311 million, offering shareholders a 36% premium. The company also advances a government-backed feasibility study for a shared processing facility and begins royalty revenue inflows.

Blue Star Helium has completed Stage 1 of its Galactica development, tying six wells into the Pinon Canyon facility and starting spot-priced helium sales. The company raised A$10 million to fund further project expansion and working capital.

Clara Resources has completed acquisition of the Mareeba Gold Project, initiating modern exploration and refocusing its portfolio on Queensland gold assets while securing fresh capital and leadership changes.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Godolphin Resources has raised A$2.5 million through a discounted share placement to fund a 2,500m diamond drilling program and metallurgical test work at its Lewis Ponds project, aiming to expand its JORC resource and advance development.

Blackstone Minerals has cleared a key regulatory hurdle at its Mankayan Copper-Gold Project, lifting a Cease and Desist Order and initiating a Pre-Feasibility Study. The company also strengthened its board with mining veteran Mark Williams and reported a solid cash position of $14.6 million.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Sunstone Metals reported robust growth at its Bramaderos gold-copper project with a 3.6Moz AuEq resource and substantial exploration targets. Drilling at Copete and Porotillo prospects confirmed mineralisation continuity, underpinning potential resource upgrades.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

AdAlta has launched its East-to-West cellular immunotherapy strategy through a co-development deal for CAR-T therapy BZDS1901, showing promising complete tumour clearance in mesothelioma patients and transferring manufacturing to Australia to boost scalability.

Tamboran Resources has closed its retail entitlement offer, adding A$24.8 million to a total equity raise of A$282.6 million to fund expanded drilling and development in the Beetaloo Basin.